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Primary biliary cirrhosis (PBC) is an autoimmune disease characterized by intrahepatic bile duct
destruction and the production of anti-mitochondrial antibodies (AMA). The absence of an animal
model has been a striking impedance in deﬁning the molecular basis of disease. Previous work has
suggested that SJL/J mice immunize with the pyruvate dehydrogenase complex (PDC-E2), the major
mitochondrial autoantigen of PBC, leads to the development of lymphoid cell inﬁltration in portal tracts
and a model system coined autoimmune cholangitis. We hypothesized that this pathology would be
augmented ifimmunization occurred in the presence of IFN-g injections. Accordingly, SJL/J micewere
immunized with PDC-E2 and, for purpose of control, a-casein. Subgroups of mice were also treated
with exogenous IFN-g. As expected, mice immunized with PDC-E2, with or without IFN-g, developed
high titer AMAs. In contrast, mice immunized with a-casein, develop antinuclear antibodies. More
importantly, the livers from mice immunized with PDC-E2 and/or those immunized with a-casein all
displayed lymphoid cell inﬁltration to the portal tracts, irrespective of bile duct size. Indeed, there was
no signiﬁcant difference between the experimental and the control groups by histologic analysis. Thus,
autoimmune cholangitis in these mice is antigen non-speciﬁc.
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INTRODUCTION
Primary biliary cirrhosis (PBC) is a chronic inﬂammatory,
organ speciﬁc autoimmune disease of the liver characte-
rized by high titer anti-mitochondrial antibodies (AMA)
and intrahepatic bile duct destruction (Nakanuma and
Ohta, 1979; Scheuer, 1994; Kaplan, 1996). The etiology
and pathogenesis of PBC are unknown. High titer AMA
react with a series of highly conserved intramitochondrial
proteins including the E2 subunit of the pyruvate
dehydrogenase complex (PDC-E2), the major autoantigen
of PBC. Whether liver injury is caused by AMA
(Malmborg et al., 1998; Feehally and Allen, 1999),
PDC-E2 speciﬁc T cells (Van de Water et al., 1997;
Shimoda et al., 1998; Inada et al., 2000), NK cells
(Tsuneyama et al., 1998; Iwata et al., 2000) or
pathological alterations of the bile ducts themselves
(Yasoshima et al., 1995; Kimura et al., 1996; Leon et al.,
1997) are all being investigated. However, it is important
to bear in mind that PBC is an autoimmune disease that
most likely develops as a multi-hit disease, not just one
insult. It has been theorized that PBC, in a genetically
susceptible host, may be initiated by a molecular mimic
(Coppel and Gershwin, 1995; Shimoda et al., 2000) or a
xenobiotic (Uibo and Salupere, 1999; Long et al., 2001).
However, to this end, no deﬁnitive causative agent has, as
yet, been identiﬁed.
The ﬁrst reported animal model for PBC was observed
in an inbred rabbit strain with spontaneous non-
suppurative cholangitis (Tison et al., 1982). However,
the speciﬁcity and repertoire of AMA in these rabbits
failed to mimic human disease. More recently, PBC
epithelial cells were injected intravenously into neona-
tally thymectomized A/J mice on the premise that
altered epithelial cells may initiate disease (Kobashi
et al., 1994; Masanaga et al., 1998). Also, injection of
C57BL/6 mice with puriﬁed PDH in LPS or injection of
recombinant polypeptides of PDC-E2 (Ide et al., 1996;
Kimura et al., 1996) have been attempted. However,
although AMAs were induced in all of these proposed
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human PBC were not induced. In contrast, a GVHD
model for PBC has also been developed which induces
histological pathology but serological responses are not
speciﬁc for mitochondrial antigens (Tanaka et al., 1999;
Zeniya, 2000). As a whole, all animal models developed
to date fail to accurately mimic human PBC by the
induction of both AMA and intrahepatic liver damage.
With these observations in mind, Jones et al. (2000)
reported the appearance of autoimmune cholangitis in
SJL/J mice following the immunization of bovine PDC-
E2, emulsiﬁed in CFA. The SJL/J mouse was chosen
because it has been successfully used as models of other
autoimmune disease, including experimental allergic
encephalomyelitis, systemic lupus erythematosus and
mercury induced immunopathology (Vidal et al., 1994;
Abedi-Valugerdi and Moller, 2000; Winer et al., 2001).
Further, T cells isolated from affected mice displayed a
mixed Th1/Th2 response when stimulated with auto-
antigen in vitro (Jones et al., 1999). IFN-g is a Th1
cytokine involved in the generation of antigen-speciﬁc
T cells and has already been shown to be involved in
induction of experimental myasthenia gravis (Wang
et al., 2000). Therefore, we hypothesized that injection
of exogenous IFN-g would enhance the development of
a PBC-like disease in SJL/J mice immunized with
bovine PDC-E2. However, we report herein that while
SJL/J mice do demonstrate evidence of signiﬁcant
cholangitis, that such cholangitis is antigen non-speciﬁc
regardless of IFN-g injection and thus not reﬂective
of PBC.
MATERIALS AND METHODS
Antigens
A mitochondrial fraction isolated from bovine heart
tissue was prepared as described previously (Fregeau
et al., 1990); native PDC-E2 was thence puriﬁed (Stanley
and Perham, 1980). As a negative control, a-casein, was
purchased from Sigma Inc. (St Louis, MO). A lipoated,
huPDC-E2 peptide (p163) spanning amino acids 163–
176 (GDLLAEIETDKATI), previously shown to be a
major T cell epitope (6–8), was synthesized by Alpha
Diagnostic International (San Antonio, TX). Peptide
purity was conﬁrmed by reversed phase HPLC.
Immunization
Female SJL/J mice were obtained from Jackson
Laboratories (Bar Harbor, ME) and all procedures
conducted according to the principles outlined in the
Guidelines of the Committee on Care and Use of
Laboratory Animals. In the ﬁrst set of experiments, mice
were immunized at 12 weeks of age with a single 200ml
intraperitoneal injection of 500mg of either bovine PDC-
E2 or a-casein emulsiﬁed in complete Freund’s adjuvant
as described (Jones et al., 2000); the complete Freund’s
adjuvant (CFA) used contained 10mg/ml Mycobacterium
tuberculosis strain H37Ra (Difco) in incomplete Freund’s
adjuvant purchased from Sigma Inc. (St Louis, MO).
In subgroups of mice, 3000units of murine recombinant
IFN-g was administered intraperitoneally twice a week for
four weeks (Kyuwa et al., 1998). The mice were divided
into the following groups: (A) PDC-E2; (B) PDC-E2 and
IFNg;( C )a-casein; and (D) a-casein and IFN-g in groups
of 8–12 animals (Table I). Mice were serially observed
and by 30 weeks of age, mice were sacriﬁced. This time
period was chosen based on earlier observations by Jones
et al. (2000). Sera were assayed for autoantibodies. In
addition, the liver, salivary gland, thymus, lung, heart,
kidney, spleen, stomach, small and large intestine, were all
removed for evaluation. Tissue specimens were ﬁxed with
10% neutral buffered formalin and embedded in parafﬁn.
Deparafﬁnized thin sections from each parafﬁn blockwere
stained with hematoxylin and eosin for histology. Because
some pilot data suggested the possibility of amyloid
deposition, a Direct Fast Scarlet stain was performed and
tissues viewed using polarized microscopy.
In the second set of experiments, two groups of ﬁve
mice were immunized at 8 weeks of age with a single
200ul intraperitoneal injection of the following: (E) 50ug
of p163 in incomplete Freund’s adjuvant (IFA); or (F) IFA
alone. Micewere serially observed and at 36 weeks of age,
they were sacriﬁced. Sera were assayed for autoanti-
bodies. The livers were removed for evaluation as
described above.
Autoantibodies
Antimitochondrial antibodies were assayed using a
combination of ELISA, immunoblotting and immunohis-
tochemical staining of HEp-2 cells. For ELISA, microtiter
plates were coated with 10mg/ml PDC-E2 suspended
TABLE I Serological and histological ﬁndings of SJL mice 30 weeks after immunization
Serological ﬁndings Histological ﬁndings
Anti-PDC-E2 (%) AMA (%) ANA (%) Mild BD injuries (%) BD loss (%) Granuloma (%) Amyloidosis (%)
PDC 100 100 0 100 0 100 100
PDC+IFN-g 100 66 33 66 0 100 66
a-Casein 0 0 100 100 0 100 0
a-Casein+IFN-g 0 0 75 75 0 100 0
BD, bile duct.
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48C. After washing three times with 0.05% Tween-20 in
PBS (PBS/Tween), plates were blocked with 3% milk in
PBS for 1h at room temperature (RT). Diluted mouse sera
(1:200) was distributed into individual wells and
incubated for 1h at RT. After washing, the plates were
incubated with 0.1ml of HRP-conjugated goat anti-mouse
immunoglobulin (Zymed, South San Francisco, CA) for
1h. Reactivity was visualized by addition of 40mM 2,20-
azinobis (3-ethylbenzthiazoline-6-sulfonic acid) dissolved
in 0.05M citric acid buffer (pH 5) containing 0.5M H2O2.
The reaction was stopped after 15min by the addition of
5% SDS. Reactivity was measured using a Wallac
spectrophotometer at a wavelength of 405nm. Known
positive and negative sera were included with each assay.
For immunoblotting, samples were suspended in 250mlo f
sample buffer (125M Tris–HCl (pH6.8) containing 4%
SDS, 20% glycerol and 5% 2-ME), boiled for 5min, and
resolved by SDS-PAGE using 1.5mm-thick slab gels with
a 4.75% stacking gel and a 10% separating gel. Separated
proteins were transferred electrophoretically to nitro-
cellulose ﬁlters purchased from Micron Separations
(Westboro, MA). After transfer, nitrocellulose ﬁlters
were cut into strips, blocked with 3% milk in PBS for
1h at RTand probed by incubation for 1h with mouse sera
diluted at 1:200. After washing with PBS/Tween, strips
were incubated for an additional hour with HRP-labeled
goat anti-mouse or anti-human polyvalent immunoglobu-
lin (1: 2000). Strips were washed and visualized with
enhanced chemiluminescent substrate purchased from
Pierce (Rockford, IL). Known AMA positive PBC sera
and control negative sera were used throughout these
studies as controls.
Immunohistochemical staining of Hep-2 cells were
performed using Hep-2 cell slides purchased from
Antibodies Inc. (Davis, CA). Slides were incubated at
RT for 1h with SJL/J mice sera, human PBC sera or
control sera diluted at 1:40. After incubation, slides were
washed in PBS for 10min. The reaction was followed by a
30min incubation with FITC-conjugated goat anti-mouse
or anti-human IgG diluted in PBS. Once again, known
positive and negative sera were used throughout.
RESULTS
Induction of Antimitochondrial Antibodies
One deﬁning serologic characteristic of PBC is the
development of high titer AMA speciﬁc for the E2 subunit
of PDC-E2 (Gershwin et al., 2000). Mice were bled and
screened for the development of AMA. All sera collected
at 7 weeks from SJL/J mice immunized with PDC-E2
(group A) showed positive reactivity against PDC-E2 by
immunoblot (Fig. 1, lanes 1 and 2). In contrast, sera
isolated at 7 weeks from mice immunized with a-casein
(group C) failed to react with PDC-E2 (Fig. 1, lane 3). All
responses from mice immunized with PDC-E2 (group A)
were similar to responses of mice immunized with PDC-
E2 plus IFN-g (group B), including reactivity with the
conserved inner lipoyl domain of PDC-E2 (data not
shown). At subsequent time points, through sacriﬁce (30
weeks), sera reactivity was very much similar to that
determined at 7 weeks post-immunization (Fig. 1, lanes 4
and 5). In contrast, sera isolated at 30 weeks from mice
immunized with a-casein (group C) failed to react with
PDC-E2 (Fig. 1, lane 6). Results performed by
immunoblot were similar to those obtained by ELISA.
Further, sera from mice primed with PDC-E2 (Groups A
and B) displayed a typical speckled (punctate) anti-
mitochondrial staining pattern (Fig. 2a). However, a single
mouse primed with PDC-E2 and who received IFN-g
(group B) demonstrated an anti-nuclear antibody pattern
at a 1:40 dilution. Sera isolated from mice immunized
with a-casein (groups C and D) also displayed weak anti-
nuclear antibody staining patterns (Fig. 2b).
Chronic Inﬂammation in Hepatic Bile Ducts
At 7 and 30 weeks post-immunization, chronic portal
inﬂammation and granulomas were observed in all mice,
irrespective of the antigen used (Table I, Fig. 3a and b).
Mild bile duct injuries were prevalent as demonstrated
by the irregular arrangement of the biliary epithelium
(Fig. 3c). Moreover, signiﬁcant lymphoid cell inﬁltration
into the biliary epithelium and isolated apoptotic biliary
FIGURE 1 Immunization of SJL/J mice with PDC-E2 induces AMA.
Sera isolated from SJL/J mice immunized with PDC-E2 as well as PBC
patient sera recognized PDC-E2(74kD) and OGDC (48kD). Lanes 1 and
2 represent sera isolated at 7 weeks from mice immunized with PDC-E2.
Lane 3 represents sera isolated at 7 weeks from a mouse immunized with
a-casein. Lanes 4 and 5 represent sera isolated at 30 weeks from mice
immunized with PDC-E2. Lane 6 represents sera isolated at 30 weeks
from mice immunized with a-casein. Lane 7 is serum from a PBC
patient.
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pathology was observed in both small and large bile ducts
(data not shown). Loss of bile ducts and destruction of the
portal tracts leading to cirrhosis failed to develop in any
mice.
Interestingly, focally globular amyloid depositions
developed along the walls of hepatic vessels in mice
immunized with bovine PDC-E2 regardless of IFN-g
treatment (Fig. 3d). These amyloid depositions were
characterized as AA type as the amyloid was sensitive to
KMnO4 treatment. In contrast, amyloid deposition was not
detectedinmiceinjectedwiththea-caseinandtherewasno
signiﬁcantdifferenceinhistologybetweena-caseingroups
treated with or without IFN-g administration (data not
shown).
Selected Organs Lack Indications of Injury Due to
Chronic Inﬂammation
Although PDC-E2 is a ubiquitous antigen found in every
cell in the body, pathology is localized to small bile ducts
and salivary glands. Thus, it was important to conﬁrm the
speciﬁcity of the immune response induced by injection of
bovine PDC-E2 by not only analyzing liver tissue, but also
selected control tissues. It was interesting that there was
lymphoid cell inﬁltration associated with mild duct
injuries in the salivary glands of mice in all groups
(Fig. 3e). Moreover, after 30 weeks, lymph node swelling
was evident in all mice. However, in contrast to the liver
and salivary glands, there were no indications of
signiﬁcant inﬂammatory responses in other organs.
Thus, immune responses to bovine PDC-E2 and a-casein
with or without IFN-g were localized to the ducts of
the liver and salivary glands and appeared to be due to
CFA or impurities in our antigen preparations.
Immunization with Incomplete Freund’s Adjuvant is
Sufﬁcient to Induce Portal Inﬂammation with Bile
Duct Invasion and Damage
The initial study by Jones et al. (23) indicated that
immunizationofSJL/JmicewithanimmunogenichuPDC-
E2peptide(p163)wasaseffectiveaswhole,bovinePDCin
inducing hepatic histologic changes characteristic of PBC.
ToeliminatedifferencesinantigenandCFApreparationas
a reason for the difference between our results and those of
Jonesetal.,studieswereconductedusingsynthesizedp163
and IFA. At 36 weeks post-immunization, we observed
signiﬁcant chronic portal inﬂammation with bile duct
invasion and damage in 2 of 5 mice injected with lipoated
p163 þ IFA (Table II). No granulomas were detected in
any of these livers. Low titers of anti-PDC-E2 antibodies
were detected by immunoblotting against puriﬁed human
PDC-E2 only in the sera of the two mice with histologic
changes(datanotshown).Pre-incubationofserawithp163
inhibited immunoblotting of huPDC-E2. However, portal
inﬂammation with bile duct invasion and damage, though
less severe, was also observed in 3 of 5 mice injected with
IFAalone.Granulomaswereobservedintwoofthesemice.
Anti-PDC-E2 antibodies were not detected in the sera of
these mice. Serum alkaline phosphatase levels were
elevated only in the mouse (E4) with the most severe
portal tract damage (data not shown). Portal inﬂammation
withbileductdamageoccurredasfrequentlyinSJL/Jmice
injected with IFA alone as compared to mice injected with
p163 and IFA.
FIGURE 2 Sera isolated from SJL/J mice immunized with PDC-E2 demonstrate a speckled mitochondrial staining pattern. (a) Sera isolated from mice
immunized with PDC-E2 diluted 1:40 showed a cytoplasmic speckled pattern corresponding to AMA. (b) Sera isolated from mice immunized with
a-casein showed a ﬁne staining pattern in the nucleus.
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Portal inﬂammation Duct invasion/damage Granuloma Hepatocellular inﬂammation
E1 0 0 0 1
E2 0 0 0 1
E3 3 2 0 1
E4 4 4 0 2
E5 0 0 0 1
F1 0 0 0 0
F2 1 1 1 1
F3 2 2 0 1
F4 1 1 1 2
F5 0 0 0 0
FIGURE 3 Chronic inﬂammation and amyloid deposition in SJL/J mice 7 and 30 weeks after immunization. (a) chronic portal inﬁltration and
granulomas (arrows) in mice immunized with PDC-E2, 7 weeks (H&E stain, 100 £ ). (b) Chronic portal inﬁltration, bile duct injuries and granulomas
(arrows) in mice immunized with a-casein, 7 weeks (H&E stain, 200 £ ). (c) Bile duct injuries and chronic portal inﬁltration in mice immunized
with a-casein, 30 weeks (H&E stain, 200 £ ). (d) Amyloid deposition in the sinusoids (arrows) of mice immunized with PDC-E2 (H&E stain, 100 £ ).
(e) Lymphoid cell inﬁltration associated with mild duct injuries in the salivary glands in mice immunized with PDC-E2 (H&E stain, 200 £ ).
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PBC is an autoimmune disease associated with an
inﬂammatory response localized to the small bile duct
cells of the liver (Gershwin et al., 2000; Ludwig, 2000).
While attempts to establish an animal model for PBC in a
number of animal species, including several strains of
mice, have had with little success (Krams et al., 1989;
Zeniya, 2000), Jones et al. have proposed an animal model
for PBC termed “experimental autoimmune cholangitis”
in which SJL/J mice are immunized with puriﬁed bovine
PDC-E2 (Jones et al., 2000). Both the use of SJL/J mice
and bovine PDC-E2 may have been important factors in
establishing this proposed model of PBC. Unclear
susceptibility factors in SJL/J mice have made these
mice useful for the establishment of models of other
autoimmune diseases (Vidal et al., 1994; Abedi-Valugerdi
and Moller, 2000; Winer et al., 2001). Additionally,
puriﬁed bovine PDC-E2 may be more efﬁcient at inducing
an immune response for several reasons. In our hands,
native PDC-E2 isolated from bovine heart tissue induces a
stronger response than E. coli-produced recombinant
protein when injected into mice (unpublished data). First,
it has been suggested that lipoic acid is essential for
optimal antigenicity (Fregeau et al., 1990; Bassendine
et al., 1998; Koike et al., 1998). Native protein is lipoated
while synthetic peptides and recombinant proteins may
not be lipoated. Second, it is important to note that bovine
PDC-E2 differs from murine PDC-E2 by 28% at the
amino acid level as determined by a protein blast.
However, the antigenic region of bovine PDC-E2,
including lipoic acid, has high homology with the murine
protein and thus select regions may be recognized as a
foreign antigen or altered self by the murine immune
system. It thus may induce a stronger immune response
against the autoantigen than a recombinant self protein or
peptide (Coppel and Gershwin, 1995; Mackay, 2000).
In the study herein, we conducted a thorough serologic
and histologic review to evaluate the premise that the
SJL/J mouse is a suitable animal model for PBC. We also
injected puriﬁed bovine PDC-E2 as the antigen to initiate
the immune response in SJL/J mice. Our control group
was not injected with CFA alone, as in the study by Jones
et al., but with a-Casein and CFA. Mild bile duct
pathology was induced by immunization with bovine
PDC-E2 emulsiﬁed in CFA. However, similar pathology
was also noted in the mice immunized with the control
protein (a-Casein) emulsiﬁed in the same adjuvant.
Antigen speciﬁc AMA were successfully induced in
experimental SJL/J mice but not control mice. However,
the characteristic bile duct injury typical of PBC failed to
develop even after 30 weeks, although mild bile duct
pathology and portal inﬂammation persisted. Furthermore,
inﬂammation and diffuse bile duct pathology were
observed, irrespective of bile duct size. In contrast, only
small bile ducts are damaged in human PBC and affected
bile ducts are distributed sparsely, not diffusely (Sasaki
et al., 2000).
To magnify the inﬂammatory environment in SJL/J
mice, we injected exogenous IFN-g but such injections
failed to alter the pathology of PBC. The addition of
IFN-g did not change the speciﬁcity or intensity of
histologic or serologic effects. These results are not
surprising since the pathology observed herein is antigen
non-speciﬁc. Hence, this system is different from the
disease associated features of IFN-g when NOD mice are
injected with exogenous cytokines (Xiang and Zaccone,
1999). Alternatively, treatment of IFN-g may cause class-
switching of antigen speciﬁc AMA to IgG1. It is possible
that IgG1 is not pathogenic. In fact, recently our lab has
demonstrated that IgA may signiﬁcantly contribute to the
pathology of PBC (Reynoso-Paz et al., 2000). In this
respect, we should note that mice do not have IgA
receptors on their bile duct cells and, in fact, have a
signiﬁcantly different mucosal immune system than that
of humans (Gershwin et al., 2000).
To eliminate non-speciﬁc effects caused by impurities
in our antigen or adjuvant preparations, SJL/J mice were
also injected with a lipoated, immunogenic huPDC-E2
peptide (aa 163–176) emulsiﬁed in IFA or with IFA alone.
Portal inﬂammation with bile duct invasion and damage
occurred with similar frequency in both groups. There is
no indication that the development of portal inﬂammation
was speciﬁc to a loss of tolerance to PDC-E2, though the
severity of inﬂammation was greater in mice expressing
anti-PDC-E2 autoantibodies. Thus, both the development
of autoantibodies and portal tract inﬂammation may
simply reﬂect the severity of the inﬂammatory response
following ip injection. SJL/J mice appear to be
predisposed to the development of portal inﬂammation
with minimal provocation.
It is of interest that systemic amyloidosis of AA type
was induced in most of the SJL/J mice immunized with
PDC-E2 but not in controls with a-casein. Generally, AA
type amyloidosis occurs secondary to systemic chronic
inﬂammatory changes such as rheumatoid arthritis and
tuberculosis. Heretofore, AA amyloidosis in mice has
been previously induced in a number of strains of mice by
repeated injections of a-casein, chemicals and endotoxin
(Skinner et al., 1977; Baumal, 1979; Rokita et al., 1989;
Kisilevsky and Young, 1994; Sipe, 1994), and in a
transgenic mouse model carrying human IL-6 gene with
mouse metallothionein-I promoter (Solomon et al., 1999).
Spontaneous amyloid deposits have also been noted in
aged SJL/J mice. In fact, the injection of amyloid
enhancing factor (AEF) together with a-casein in CFA
induced AA amyloidosis in SJL/J mice, while a-casein
alone did not induce amyloidosis (Rokita et al.,1989). Our
ﬁndings are in agreement with these ﬁndings but not those
of Jones et al. (1999).
The SJL/J mouse is an interesting model for a number
of diseases and it remains possible that with further study,
signiﬁcant information may be forthcoming on the
inﬂammatory environment within the liver and salivary
glands. However, it appears that such responses are
antigen non-speciﬁc.
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